Bausch + Lomb advances eye health therapies and receives brokerage ratings

Bausch + Lomb has announced that two of its first-in-class pharmaceutical pipeline assets will advance to new clinical trials following recent results. One key development is a dual-action eye drop designed to treat dry eye disease by simultaneously addressing ocular surface inflammation and tear evaporation. This treatment combines 5% lifitegrast and perfluorohexyloctane (PFHO). Phase 2 study results have supported the advancement of this combination therapy to Phase 3 trials.

In financial news, Bausch + Lomb (NYSE: BLCO) has received a consensus “Hold” recommendation from thirteen brokerage firms. While analyst opinions vary—with five “buy” ratings, seven “hold” ratings, and one “sell” rating—the average one-year price objective is $18.75. Recent individual analyst actions include Citigroup and UBS Group issuing “buy” ratings with price targets of $21.00, while Deutsche Bank set a $16.00 price objective.